| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
Articles |
, Epidermal Growth Factor (EGF), and EGF Receptor Expression in the Rat Uterus and Vagina1
Department of Pharmacology and Toxicology, and University of Alabama at Birmingham Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama 35294
Abstract
Epidemiological reports and laboratory data have associated soy and
genistein with reduced incidence of uterine, breast, and prostate
cancers, cardiovascular disease and osteoporosis, and lower total blood
cholesterol. The aim of this study was to investigate the effect of
genistein in the uterus and vagina of rats, focusing our attention on
the distribution of transforming growth factor (TGF)
, epidermal
growth factor (EGF), and EGF receptor. A pharmacological dose of
genistein (500 µg/g body weight) injected in rats on days 16, 18, and
20 postpartum resulted in significant uterine wet weight gain, with
hypertrophy of the luminal and glandular epithelium of the uteri, and
squamous epithelium of the vagina in 21-day-old animals. At 50 days of
age, hypertrophy was no longer evident in the uterus and vagina.
Prepubertal genistein treatment resulted in significantly increased EGF
immunostaining in individual stromal cells and reduced EGF receptor
immunostaining in blood vessels of the uterus. Genistein-treated rats
had decreased TGF-
immunostaining in glandular and luminal
epithelium and a slight increase in EGF receptor immunostaining in
stromal cells of the uterus. This suggests paracrine interaction
between cells elevating the level of EGF ligand in the stroma and the
EGF receptor in the luminal and glandular epithelium, resulting in
uterine hypertrophy. In the vagina, genistein did not cause significant
alterations to the EGF-signaling pathway in 21- and 50-day-old rats. We
conclude that pharmacological doses of genistein during the prepubertal
period can modulate the EGF-signaling pathway in the uterus and exert a
uterotrophic response in a short-term manner.
This article has been cited by other articles:
![]() |
G. E. Akbas, X. Fei, and H. S. Taylor Regulation of HOXA10 expression by phytoestrogens Am J Physiol Endocrinol Metab, February 1, 2007; 292(2): E435 - E442. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |